GlassScriptPhysician profile
Steven Kory
NPI 1467489450
$627,917.17
in general payments reported to CMS, 2019-2025
22 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $57K · 2021: $57K · 2022: $78K · 2023: $111K · 2024: $118K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300K · Travel and Lodging: $23K · Food and Beverage: $9,944 · Consulting Fee: $7,300 · Honoraria: $2,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300,265.50 |
| Travel and Lodging | $23,384.16 |
| Food and Beverage | $9,944.10 |
| Consulting Fee | $7,300.00 |
| Honoraria | $2,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163,289.76 | 2020-2025 | Caplyta |
| Abbvie INC. | $116,621.74 | 2021-2025 | |
| Allergan, INC. | $95,395.47 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $81,321.90 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $70,358.47 | 2021-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $38,385.50 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Eisai INC. | $20,693.70 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $10,523.98 | 2019-2023 | Invega Trinza, Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $9,155.02 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $8,651.80 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $7,228.81 | 2019-2022 | |
| Indivior INC. | $3,903.64 | 2019-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $456.69 | 2021-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $432.64 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $420.67 | 2021-2024 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $353.18 | 2020-2023 | Aristada, Lybalvi |
| Corium, LLC | $296.66 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $289.37 | 2022-2024 | Auvelity |
| Braeburn INC. | $38.07 | 2023-2024 | Brixadi |
| Merck Sharp & Dohme LLC | $34.47 | 2021 | |
| Harmony Biosciences LLC | $34.41 | 2022 | |
| Alfasigma USA, INC. | $31.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.